nodes	percent_of_prediction	percent_of_DWPC	metapath
Losartan—UGT2B7—urinary bladder cancer	0.462	1	CbGaD
Losartan—UGT2B7—Epirubicin—urinary bladder cancer	0.0457	0.162	CbGbCtD
Losartan—UGT1A1—Etoposide—urinary bladder cancer	0.0308	0.109	CbGbCtD
Losartan—ABCB1—Mitomycin—urinary bladder cancer	0.0297	0.105	CbGbCtD
Losartan—SLCO1B3—Methotrexate—urinary bladder cancer	0.0242	0.0856	CbGbCtD
Losartan—SLCO1B1—Methotrexate—urinary bladder cancer	0.0141	0.0499	CbGbCtD
Losartan—ALB—Fluorouracil—urinary bladder cancer	0.014	0.0495	CbGbCtD
Losartan—CYP3A4—Thiotepa—urinary bladder cancer	0.0135	0.0478	CbGbCtD
Losartan—CYP2C8—Fluorouracil—urinary bladder cancer	0.0108	0.0383	CbGbCtD
Losartan—CYP3A5—Etoposide—urinary bladder cancer	0.00937	0.0332	CbGbCtD
Losartan—SLC22A6—Methotrexate—urinary bladder cancer	0.00905	0.0321	CbGbCtD
Losartan—CYP2C8—Etoposide—urinary bladder cancer	0.00901	0.0319	CbGbCtD
Losartan—ABCB1—Gemcitabine—urinary bladder cancer	0.00855	0.0303	CbGbCtD
Losartan—CYP1A2—Fluorouracil—urinary bladder cancer	0.00836	0.0296	CbGbCtD
Losartan—ALB—Methotrexate—urinary bladder cancer	0.00771	0.0273	CbGbCtD
Losartan—CYP2C9—Fluorouracil—urinary bladder cancer	0.00753	0.0267	CbGbCtD
Losartan—CYP1A2—Etoposide—urinary bladder cancer	0.00698	0.0247	CbGbCtD
Losartan—CYP2C9—Cisplatin—urinary bladder cancer	0.0064	0.0227	CbGbCtD
Losartan—ABCB1—Cisplatin—urinary bladder cancer	0.00621	0.022	CbGbCtD
Losartan—ABCB1—Etoposide—urinary bladder cancer	0.0061	0.0216	CbGbCtD
Losartan—UGT2B17—prostate gland—urinary bladder cancer	0.00593	0.102	CbGeAlD
Losartan—UGT2B17—epithelium—urinary bladder cancer	0.00436	0.0751	CbGeAlD
Losartan—ABCB1—Doxorubicin—urinary bladder cancer	0.00416	0.0147	CbGbCtD
Losartan—ABCB1—Methotrexate—urinary bladder cancer	0.00403	0.0143	CbGbCtD
Losartan—CYP3A4—Etoposide—urinary bladder cancer	0.00366	0.013	CbGbCtD
Losartan—UGT1A1—urine—urinary bladder cancer	0.00321	0.0553	CbGeAlD
Losartan—SLC2A9—prostate gland—urinary bladder cancer	0.00263	0.0452	CbGeAlD
Losartan—SLC22A12—renal system—urinary bladder cancer	0.00261	0.0449	CbGeAlD
Losartan—ACE—umbilical vein—urinary bladder cancer	0.00257	0.0442	CbGeAlD
Losartan—CYP3A4—Doxorubicin—urinary bladder cancer	0.00249	0.00883	CbGbCtD
Losartan—UGT1A10—renal system—urinary bladder cancer	0.00229	0.0393	CbGeAlD
Losartan—SLC2A9—seminal vesicle—urinary bladder cancer	0.00222	0.0383	CbGeAlD
Losartan—ACE—urine—urinary bladder cancer	0.00207	0.0357	CbGeAlD
Losartan—SLC2A9—renal system—urinary bladder cancer	0.00179	0.0308	CbGeAlD
Losartan—CYP2C19—urine—urinary bladder cancer	0.00174	0.03	CbGeAlD
Losartan—SLC2A9—female reproductive system—urinary bladder cancer	0.00143	0.0247	CbGeAlD
Losartan—CYP1A2—urine—urinary bladder cancer	0.00142	0.0245	CbGeAlD
Losartan—UGT2B7—prostate gland—urinary bladder cancer	0.00136	0.0234	CbGeAlD
Losartan—CYP2C9—urine—urinary bladder cancer	0.00135	0.0233	CbGeAlD
Losartan—UGT1A1—prostate gland—urinary bladder cancer	0.00115	0.0199	CbGeAlD
Losartan—CYP3A4—urine—urinary bladder cancer	0.00103	0.0177	CbGeAlD
Losartan—AGTR1—prostate gland—urinary bladder cancer	0.00101	0.0173	CbGeAlD
Losartan—UGT2B7—renal system—urinary bladder cancer	0.000925	0.0159	CbGeAlD
Losartan—SLC2A9—lymph node—urinary bladder cancer	0.000839	0.0144	CbGeAlD
Losartan—SLCO1B3—vagina—urinary bladder cancer	0.000819	0.0141	CbGeAlD
Losartan—UGT1A1—renal system—urinary bladder cancer	0.000786	0.0135	CbGeAlD
Losartan—ACE—prostate gland—urinary bladder cancer	0.000743	0.0128	CbGeAlD
Losartan—UGT2B7—female reproductive system—urinary bladder cancer	0.000741	0.0128	CbGeAlD
Losartan—AGTR1—epithelium—urinary bladder cancer	0.00074	0.0127	CbGeAlD
Losartan—AGTR1—smooth muscle tissue—urinary bladder cancer	0.000713	0.0123	CbGeAlD
Losartan—AGTR1—renal system—urinary bladder cancer	0.000686	0.0118	CbGeAlD
Losartan—SLCO1B1—renal system—urinary bladder cancer	0.000654	0.0113	CbGeAlD
Losartan—Telmisartan—PPARG—urinary bladder cancer	0.000641	1	CrCbGaD
Losartan—ACE—seminal vesicle—urinary bladder cancer	0.000629	0.0108	CbGeAlD
Losartan—AGTR1—female reproductive system—urinary bladder cancer	0.00055	0.00946	CbGeAlD
Losartan—ACE—epithelium—urinary bladder cancer	0.000546	0.00941	CbGeAlD
Losartan—ACE—smooth muscle tissue—urinary bladder cancer	0.000526	0.00906	CbGeAlD
Losartan—SLCO1B1—female reproductive system—urinary bladder cancer	0.000524	0.00902	CbGeAlD
Losartan—ACE—renal system—urinary bladder cancer	0.000507	0.00872	CbGeAlD
Losartan—ACE—urethra—urinary bladder cancer	0.000498	0.00857	CbGeAlD
Losartan—AGTR1—vagina—urinary bladder cancer	0.000497	0.00856	CbGeAlD
Losartan—CYP3A5—prostate gland—urinary bladder cancer	0.000493	0.00848	CbGeAlD
Losartan—ACE—female reproductive system—urinary bladder cancer	0.000406	0.00699	CbGeAlD
Losartan—CYP2C8—renal system—urinary bladder cancer	0.000372	0.00641	CbGeAlD
Losartan—CYP1A2—renal system—urinary bladder cancer	0.000348	0.00599	CbGeAlD
Losartan—CYP3A5—renal system—urinary bladder cancer	0.000336	0.00578	CbGeAlD
Losartan—AGTR1—lymph node—urinary bladder cancer	0.000321	0.00554	CbGeAlD
Losartan—CYP2C19—vagina—urinary bladder cancer	0.000309	0.00532	CbGeAlD
Losartan—CYP2C8—female reproductive system—urinary bladder cancer	0.000298	0.00513	CbGeAlD
Losartan—CYP2C8—vagina—urinary bladder cancer	0.000269	0.00464	CbGeAlD
Losartan—CYP2C9—female reproductive system—urinary bladder cancer	0.000265	0.00456	CbGeAlD
Losartan—ABCB1—prostate gland—urinary bladder cancer	0.000262	0.00451	CbGeAlD
Losartan—CYP3A4—renal system—urinary bladder cancer	0.000252	0.00434	CbGeAlD
Losartan—ALB—lymph node—urinary bladder cancer	0.000248	0.00427	CbGeAlD
Losartan—CYP3A5—vagina—urinary bladder cancer	0.000243	0.00419	CbGeAlD
Losartan—ACE—lymph node—urinary bladder cancer	0.000237	0.00409	CbGeAlD
Losartan—ABCB1—seminal vesicle—urinary bladder cancer	0.000221	0.00381	CbGeAlD
Losartan—CYP3A4—female reproductive system—urinary bladder cancer	0.000202	0.00347	CbGeAlD
Losartan—ABCB1—epithelium—urinary bladder cancer	0.000192	0.00331	CbGeAlD
Losartan—ABCB1—renal system—urinary bladder cancer	0.000178	0.00307	CbGeAlD
Losartan—ABCB1—urethra—urinary bladder cancer	0.000175	0.00302	CbGeAlD
Losartan—ABCB1—female reproductive system—urinary bladder cancer	0.000143	0.00246	CbGeAlD
Losartan—ABCB1—vagina—urinary bladder cancer	0.000129	0.00222	CbGeAlD
Losartan—ABCB1—lymph node—urinary bladder cancer	8.36e-05	0.00144	CbGeAlD
Losartan—Hepatitis—Methotrexate—urinary bladder cancer	8.02e-05	0.000817	CcSEcCtD
Losartan—Sweating—Epirubicin—urinary bladder cancer	8.02e-05	0.000817	CcSEcCtD
Losartan—Pollakiuria—Doxorubicin—urinary bladder cancer	8.02e-05	0.000817	CcSEcCtD
Losartan—Asthenia—Gemcitabine—urinary bladder cancer	7.99e-05	0.000815	CcSEcCtD
Losartan—Pharyngitis—Methotrexate—urinary bladder cancer	7.96e-05	0.000811	CcSEcCtD
Losartan—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	7.92e-05	0.000807	CcSEcCtD
Losartan—Weight increased—Doxorubicin—urinary bladder cancer	7.9e-05	0.000805	CcSEcCtD
Losartan—Epistaxis—Epirubicin—urinary bladder cancer	7.89e-05	0.000804	CcSEcCtD
Losartan—Pruritus—Gemcitabine—urinary bladder cancer	7.88e-05	0.000803	CcSEcCtD
Losartan—Nausea—Thiotepa—urinary bladder cancer	7.87e-05	0.000802	CcSEcCtD
Losartan—Sinusitis—Epirubicin—urinary bladder cancer	7.85e-05	0.000799	CcSEcCtD
Losartan—Feeling abnormal—Etoposide—urinary bladder cancer	7.84e-05	0.000799	CcSEcCtD
Losartan—Hyperglycaemia—Doxorubicin—urinary bladder cancer	7.83e-05	0.000798	CcSEcCtD
Losartan—Agranulocytosis—Epirubicin—urinary bladder cancer	7.8e-05	0.000795	CcSEcCtD
Losartan—Pneumonia—Doxorubicin—urinary bladder cancer	7.78e-05	0.000793	CcSEcCtD
Losartan—Gastrointestinal pain—Etoposide—urinary bladder cancer	7.78e-05	0.000793	CcSEcCtD
Losartan—Pruritus—Fluorouracil—urinary bladder cancer	7.75e-05	0.00079	CcSEcCtD
Losartan—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	7.67e-05	0.000782	CcSEcCtD
Losartan—Hypersensitivity—Cisplatin—urinary bladder cancer	7.65e-05	0.00078	CcSEcCtD
Losartan—Diarrhoea—Gemcitabine—urinary bladder cancer	7.62e-05	0.000777	CcSEcCtD
Losartan—Renal failure—Doxorubicin—urinary bladder cancer	7.61e-05	0.000775	CcSEcCtD
Losartan—Erythema multiforme—Methotrexate—urinary bladder cancer	7.58e-05	0.000773	CcSEcCtD
Losartan—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	7.58e-05	0.000773	CcSEcCtD
Losartan—Urticaria—Etoposide—urinary bladder cancer	7.56e-05	0.00077	CcSEcCtD
Losartan—Jaundice—Doxorubicin—urinary bladder cancer	7.54e-05	0.000768	CcSEcCtD
Losartan—Rhinitis—Epirubicin—urinary bladder cancer	7.53e-05	0.000767	CcSEcCtD
Losartan—Abdominal pain—Etoposide—urinary bladder cancer	7.52e-05	0.000766	CcSEcCtD
Losartan—Body temperature increased—Etoposide—urinary bladder cancer	7.52e-05	0.000766	CcSEcCtD
Losartan—Urinary tract infection—Doxorubicin—urinary bladder cancer	7.52e-05	0.000766	CcSEcCtD
Losartan—Conjunctivitis—Doxorubicin—urinary bladder cancer	7.52e-05	0.000766	CcSEcCtD
Losartan—Hepatitis—Epirubicin—urinary bladder cancer	7.51e-05	0.000765	CcSEcCtD
Losartan—Diarrhoea—Fluorouracil—urinary bladder cancer	7.5e-05	0.000764	CcSEcCtD
Losartan—Tinnitus—Methotrexate—urinary bladder cancer	7.48e-05	0.000762	CcSEcCtD
Losartan—Hypoaesthesia—Epirubicin—urinary bladder cancer	7.47e-05	0.000761	CcSEcCtD
Losartan—Asthenia—Cisplatin—urinary bladder cancer	7.45e-05	0.000759	CcSEcCtD
Losartan—Pharyngitis—Epirubicin—urinary bladder cancer	7.45e-05	0.000759	CcSEcCtD
Losartan—Sweating—Doxorubicin—urinary bladder cancer	7.42e-05	0.000756	CcSEcCtD
Losartan—Epistaxis—Doxorubicin—urinary bladder cancer	7.3e-05	0.000744	CcSEcCtD
Losartan—Angiopathy—Methotrexate—urinary bladder cancer	7.28e-05	0.000742	CcSEcCtD
Losartan—Sinusitis—Doxorubicin—urinary bladder cancer	7.26e-05	0.00074	CcSEcCtD
Losartan—Dizziness—Fluorouracil—urinary bladder cancer	7.24e-05	0.000738	CcSEcCtD
Losartan—Agranulocytosis—Doxorubicin—urinary bladder cancer	7.22e-05	0.000736	CcSEcCtD
Losartan—Diarrhoea—Cisplatin—urinary bladder cancer	7.11e-05	0.000724	CcSEcCtD
Losartan—Erythema multiforme—Epirubicin—urinary bladder cancer	7.1e-05	0.000723	CcSEcCtD
Losartan—Alopecia—Methotrexate—urinary bladder cancer	7.09e-05	0.000722	CcSEcCtD
Losartan—Vomiting—Gemcitabine—urinary bladder cancer	7.08e-05	0.000722	CcSEcCtD
Losartan—Rash—Gemcitabine—urinary bladder cancer	7.03e-05	0.000716	CcSEcCtD
Losartan—Dermatitis—Gemcitabine—urinary bladder cancer	7.02e-05	0.000715	CcSEcCtD
Losartan—Hypersensitivity—Etoposide—urinary bladder cancer	7.01e-05	0.000714	CcSEcCtD
Losartan—Tinnitus—Epirubicin—urinary bladder cancer	7e-05	0.000713	CcSEcCtD
Losartan—Erythema—Methotrexate—urinary bladder cancer	6.98e-05	0.000711	CcSEcCtD
Losartan—Headache—Gemcitabine—urinary bladder cancer	6.98e-05	0.000711	CcSEcCtD
Losartan—Flushing—Epirubicin—urinary bladder cancer	6.97e-05	0.00071	CcSEcCtD
Losartan—Vomiting—Fluorouracil—urinary bladder cancer	6.97e-05	0.00071	CcSEcCtD
Losartan—Rhinitis—Doxorubicin—urinary bladder cancer	6.96e-05	0.000709	CcSEcCtD
Losartan—Hepatitis—Doxorubicin—urinary bladder cancer	6.95e-05	0.000708	CcSEcCtD
Losartan—Hypoaesthesia—Doxorubicin—urinary bladder cancer	6.91e-05	0.000704	CcSEcCtD
Losartan—Rash—Fluorouracil—urinary bladder cancer	6.91e-05	0.000704	CcSEcCtD
Losartan—Dermatitis—Fluorouracil—urinary bladder cancer	6.9e-05	0.000703	CcSEcCtD
Losartan—Pharyngitis—Doxorubicin—urinary bladder cancer	6.89e-05	0.000702	CcSEcCtD
Losartan—Headache—Fluorouracil—urinary bladder cancer	6.86e-05	0.000699	CcSEcCtD
Losartan—Dysgeusia—Methotrexate—urinary bladder cancer	6.84e-05	0.000697	CcSEcCtD
Losartan—Asthenia—Etoposide—urinary bladder cancer	6.83e-05	0.000696	CcSEcCtD
Losartan—Angiopathy—Epirubicin—urinary bladder cancer	6.81e-05	0.000694	CcSEcCtD
Losartan—Back pain—Methotrexate—urinary bladder cancer	6.75e-05	0.000688	CcSEcCtD
Losartan—Pruritus—Etoposide—urinary bladder cancer	6.73e-05	0.000686	CcSEcCtD
Losartan—Arrhythmia—Epirubicin—urinary bladder cancer	6.71e-05	0.000683	CcSEcCtD
Losartan—Alopecia—Epirubicin—urinary bladder cancer	6.63e-05	0.000676	CcSEcCtD
Losartan—Nausea—Gemcitabine—urinary bladder cancer	6.62e-05	0.000674	CcSEcCtD
Losartan—Vomiting—Cisplatin—urinary bladder cancer	6.6e-05	0.000673	CcSEcCtD
Losartan—Vision blurred—Methotrexate—urinary bladder cancer	6.58e-05	0.000671	CcSEcCtD
Losartan—Erythema multiforme—Doxorubicin—urinary bladder cancer	6.57e-05	0.000669	CcSEcCtD
Losartan—Rash—Cisplatin—urinary bladder cancer	6.55e-05	0.000667	CcSEcCtD
Losartan—Dermatitis—Cisplatin—urinary bladder cancer	6.54e-05	0.000667	CcSEcCtD
Losartan—Erythema—Epirubicin—urinary bladder cancer	6.53e-05	0.000666	CcSEcCtD
Losartan—Diarrhoea—Etoposide—urinary bladder cancer	6.51e-05	0.000663	CcSEcCtD
Losartan—Nausea—Fluorouracil—urinary bladder cancer	6.51e-05	0.000663	CcSEcCtD
Losartan—Ill-defined disorder—Methotrexate—urinary bladder cancer	6.48e-05	0.00066	CcSEcCtD
Losartan—Tinnitus—Doxorubicin—urinary bladder cancer	6.48e-05	0.00066	CcSEcCtD
Losartan—Anaemia—Methotrexate—urinary bladder cancer	6.45e-05	0.000658	CcSEcCtD
Losartan—Flushing—Doxorubicin—urinary bladder cancer	6.45e-05	0.000657	CcSEcCtD
Losartan—Flatulence—Epirubicin—urinary bladder cancer	6.44e-05	0.000656	CcSEcCtD
Losartan—Tension—Epirubicin—urinary bladder cancer	6.41e-05	0.000653	CcSEcCtD
Losartan—Dysgeusia—Epirubicin—urinary bladder cancer	6.4e-05	0.000652	CcSEcCtD
Losartan—Nervousness—Epirubicin—urinary bladder cancer	6.35e-05	0.000647	CcSEcCtD
Losartan—Back pain—Epirubicin—urinary bladder cancer	6.32e-05	0.000644	CcSEcCtD
Losartan—Angiopathy—Doxorubicin—urinary bladder cancer	6.3e-05	0.000642	CcSEcCtD
Losartan—Malaise—Methotrexate—urinary bladder cancer	6.3e-05	0.000642	CcSEcCtD
Losartan—Dizziness—Etoposide—urinary bladder cancer	6.29e-05	0.000641	CcSEcCtD
Losartan—Muscle spasms—Epirubicin—urinary bladder cancer	6.28e-05	0.00064	CcSEcCtD
Losartan—Vertigo—Methotrexate—urinary bladder cancer	6.27e-05	0.000639	CcSEcCtD
Losartan—Leukopenia—Methotrexate—urinary bladder cancer	6.25e-05	0.000637	CcSEcCtD
Losartan—Arrhythmia—Doxorubicin—urinary bladder cancer	6.2e-05	0.000632	CcSEcCtD
Losartan—Nausea—Cisplatin—urinary bladder cancer	6.17e-05	0.000629	CcSEcCtD
Losartan—Vision blurred—Epirubicin—urinary bladder cancer	6.16e-05	0.000627	CcSEcCtD
Losartan—Alopecia—Doxorubicin—urinary bladder cancer	6.14e-05	0.000625	CcSEcCtD
Losartan—Cough—Methotrexate—urinary bladder cancer	6.09e-05	0.000621	CcSEcCtD
Losartan—Ill-defined disorder—Epirubicin—urinary bladder cancer	6.06e-05	0.000618	CcSEcCtD
Losartan—Vomiting—Etoposide—urinary bladder cancer	6.05e-05	0.000616	CcSEcCtD
Losartan—Erythema—Doxorubicin—urinary bladder cancer	6.05e-05	0.000616	CcSEcCtD
Losartan—Anaemia—Epirubicin—urinary bladder cancer	6.04e-05	0.000615	CcSEcCtD
Losartan—Agitation—Epirubicin—urinary bladder cancer	6.01e-05	0.000612	CcSEcCtD
Losartan—Rash—Etoposide—urinary bladder cancer	6e-05	0.000611	CcSEcCtD
Losartan—Dermatitis—Etoposide—urinary bladder cancer	5.99e-05	0.000611	CcSEcCtD
Losartan—Headache—Etoposide—urinary bladder cancer	5.96e-05	0.000607	CcSEcCtD
Losartan—Flatulence—Doxorubicin—urinary bladder cancer	5.96e-05	0.000607	CcSEcCtD
Losartan—Arthralgia—Methotrexate—urinary bladder cancer	5.94e-05	0.000606	CcSEcCtD
Losartan—Myalgia—Methotrexate—urinary bladder cancer	5.94e-05	0.000606	CcSEcCtD
Losartan—Chest pain—Methotrexate—urinary bladder cancer	5.94e-05	0.000606	CcSEcCtD
Losartan—Tension—Doxorubicin—urinary bladder cancer	5.93e-05	0.000605	CcSEcCtD
Losartan—Dysgeusia—Doxorubicin—urinary bladder cancer	5.92e-05	0.000603	CcSEcCtD
Losartan—Malaise—Epirubicin—urinary bladder cancer	5.89e-05	0.0006	CcSEcCtD
Losartan—Discomfort—Methotrexate—urinary bladder cancer	5.87e-05	0.000598	CcSEcCtD
Losartan—Nervousness—Doxorubicin—urinary bladder cancer	5.87e-05	0.000598	CcSEcCtD
Losartan—Vertigo—Epirubicin—urinary bladder cancer	5.87e-05	0.000598	CcSEcCtD
Losartan—Syncope—Epirubicin—urinary bladder cancer	5.86e-05	0.000597	CcSEcCtD
Losartan—Leukopenia—Epirubicin—urinary bladder cancer	5.85e-05	0.000596	CcSEcCtD
Losartan—Back pain—Doxorubicin—urinary bladder cancer	5.85e-05	0.000596	CcSEcCtD
Losartan—Muscle spasms—Doxorubicin—urinary bladder cancer	5.81e-05	0.000592	CcSEcCtD
Losartan—Palpitations—Epirubicin—urinary bladder cancer	5.77e-05	0.000588	CcSEcCtD
Losartan—Confusional state—Methotrexate—urinary bladder cancer	5.75e-05	0.000585	CcSEcCtD
Losartan—Loss of consciousness—Epirubicin—urinary bladder cancer	5.74e-05	0.000585	CcSEcCtD
Losartan—Cough—Epirubicin—urinary bladder cancer	5.7e-05	0.000581	CcSEcCtD
Losartan—Anaphylactic shock—Methotrexate—urinary bladder cancer	5.7e-05	0.000581	CcSEcCtD
Losartan—Vision blurred—Doxorubicin—urinary bladder cancer	5.7e-05	0.000581	CcSEcCtD
Losartan—Infection—Methotrexate—urinary bladder cancer	5.66e-05	0.000577	CcSEcCtD
Losartan—Nausea—Etoposide—urinary bladder cancer	5.65e-05	0.000576	CcSEcCtD
Losartan—Ill-defined disorder—Doxorubicin—urinary bladder cancer	5.61e-05	0.000572	CcSEcCtD
Losartan—Nervous system disorder—Methotrexate—urinary bladder cancer	5.59e-05	0.000569	CcSEcCtD
Losartan—Anaemia—Doxorubicin—urinary bladder cancer	5.59e-05	0.000569	CcSEcCtD
Losartan—Thrombocytopenia—Methotrexate—urinary bladder cancer	5.58e-05	0.000569	CcSEcCtD
Losartan—Chest pain—Epirubicin—urinary bladder cancer	5.56e-05	0.000567	CcSEcCtD
Losartan—Arthralgia—Epirubicin—urinary bladder cancer	5.56e-05	0.000567	CcSEcCtD
Losartan—Myalgia—Epirubicin—urinary bladder cancer	5.56e-05	0.000567	CcSEcCtD
Losartan—Agitation—Doxorubicin—urinary bladder cancer	5.56e-05	0.000566	CcSEcCtD
Losartan—Anxiety—Epirubicin—urinary bladder cancer	5.54e-05	0.000565	CcSEcCtD
Losartan—Hyperhidrosis—Methotrexate—urinary bladder cancer	5.51e-05	0.000561	CcSEcCtD
Losartan—Discomfort—Epirubicin—urinary bladder cancer	5.5e-05	0.00056	CcSEcCtD
Losartan—Malaise—Doxorubicin—urinary bladder cancer	5.45e-05	0.000556	CcSEcCtD
Losartan—Dry mouth—Epirubicin—urinary bladder cancer	5.44e-05	0.000554	CcSEcCtD
Losartan—Vertigo—Doxorubicin—urinary bladder cancer	5.43e-05	0.000553	CcSEcCtD
Losartan—Anorexia—Methotrexate—urinary bladder cancer	5.43e-05	0.000553	CcSEcCtD
Losartan—Syncope—Doxorubicin—urinary bladder cancer	5.42e-05	0.000552	CcSEcCtD
Losartan—Leukopenia—Doxorubicin—urinary bladder cancer	5.41e-05	0.000551	CcSEcCtD
Losartan—Confusional state—Epirubicin—urinary bladder cancer	5.38e-05	0.000548	CcSEcCtD
Losartan—Palpitations—Doxorubicin—urinary bladder cancer	5.34e-05	0.000544	CcSEcCtD
Losartan—Oedema—Epirubicin—urinary bladder cancer	5.33e-05	0.000543	CcSEcCtD
Losartan—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.33e-05	0.000543	CcSEcCtD
Losartan—Hypotension—Methotrexate—urinary bladder cancer	5.33e-05	0.000543	CcSEcCtD
Losartan—Loss of consciousness—Doxorubicin—urinary bladder cancer	5.31e-05	0.000541	CcSEcCtD
Losartan—Infection—Epirubicin—urinary bladder cancer	5.3e-05	0.00054	CcSEcCtD
Losartan—Cough—Doxorubicin—urinary bladder cancer	5.28e-05	0.000538	CcSEcCtD
Losartan—Shock—Epirubicin—urinary bladder cancer	5.25e-05	0.000535	CcSEcCtD
Losartan—Nervous system disorder—Epirubicin—urinary bladder cancer	5.23e-05	0.000533	CcSEcCtD
Losartan—Thrombocytopenia—Epirubicin—urinary bladder cancer	5.22e-05	0.000532	CcSEcCtD
Losartan—Tachycardia—Epirubicin—urinary bladder cancer	5.21e-05	0.00053	CcSEcCtD
Losartan—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.19e-05	0.000529	CcSEcCtD
Losartan—Hyperhidrosis—Epirubicin—urinary bladder cancer	5.16e-05	0.000525	CcSEcCtD
Losartan—Insomnia—Methotrexate—urinary bladder cancer	5.15e-05	0.000525	CcSEcCtD
Losartan—Myalgia—Doxorubicin—urinary bladder cancer	5.15e-05	0.000524	CcSEcCtD
Losartan—Arthralgia—Doxorubicin—urinary bladder cancer	5.15e-05	0.000524	CcSEcCtD
Losartan—Chest pain—Doxorubicin—urinary bladder cancer	5.15e-05	0.000524	CcSEcCtD
Losartan—Anxiety—Doxorubicin—urinary bladder cancer	5.13e-05	0.000523	CcSEcCtD
Losartan—Paraesthesia—Methotrexate—urinary bladder cancer	5.12e-05	0.000521	CcSEcCtD
Losartan—Discomfort—Doxorubicin—urinary bladder cancer	5.09e-05	0.000518	CcSEcCtD
Losartan—Anorexia—Epirubicin—urinary bladder cancer	5.08e-05	0.000518	CcSEcCtD
Losartan—Dyspnoea—Methotrexate—urinary bladder cancer	5.08e-05	0.000518	CcSEcCtD
Losartan—Somnolence—Methotrexate—urinary bladder cancer	5.07e-05	0.000516	CcSEcCtD
Losartan—Dry mouth—Doxorubicin—urinary bladder cancer	5.03e-05	0.000513	CcSEcCtD
Losartan—Dyspepsia—Methotrexate—urinary bladder cancer	5.02e-05	0.000511	CcSEcCtD
Losartan—Hypotension—Epirubicin—urinary bladder cancer	4.98e-05	0.000508	CcSEcCtD
Losartan—Confusional state—Doxorubicin—urinary bladder cancer	4.98e-05	0.000507	CcSEcCtD
Losartan—Decreased appetite—Methotrexate—urinary bladder cancer	4.95e-05	0.000505	CcSEcCtD
Losartan—Anaphylactic shock—Doxorubicin—urinary bladder cancer	4.93e-05	0.000503	CcSEcCtD
Losartan—Oedema—Doxorubicin—urinary bladder cancer	4.93e-05	0.000503	CcSEcCtD
Losartan—Fatigue—Methotrexate—urinary bladder cancer	4.91e-05	0.000501	CcSEcCtD
Losartan—Infection—Doxorubicin—urinary bladder cancer	4.9e-05	0.0005	CcSEcCtD
Losartan—Pain—Methotrexate—urinary bladder cancer	4.87e-05	0.000497	CcSEcCtD
Losartan—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	4.86e-05	0.000495	CcSEcCtD
Losartan—Shock—Doxorubicin—urinary bladder cancer	4.85e-05	0.000495	CcSEcCtD
Losartan—Nervous system disorder—Doxorubicin—urinary bladder cancer	4.84e-05	0.000493	CcSEcCtD
Losartan—Thrombocytopenia—Doxorubicin—urinary bladder cancer	4.83e-05	0.000492	CcSEcCtD
Losartan—Insomnia—Epirubicin—urinary bladder cancer	4.82e-05	0.000491	CcSEcCtD
Losartan—Tachycardia—Doxorubicin—urinary bladder cancer	4.82e-05	0.000491	CcSEcCtD
Losartan—Paraesthesia—Epirubicin—urinary bladder cancer	4.79e-05	0.000488	CcSEcCtD
Losartan—Hyperhidrosis—Doxorubicin—urinary bladder cancer	4.77e-05	0.000486	CcSEcCtD
Losartan—Dyspnoea—Epirubicin—urinary bladder cancer	4.75e-05	0.000484	CcSEcCtD
Losartan—Somnolence—Epirubicin—urinary bladder cancer	4.74e-05	0.000483	CcSEcCtD
Losartan—Anorexia—Doxorubicin—urinary bladder cancer	4.7e-05	0.000479	CcSEcCtD
Losartan—Feeling abnormal—Methotrexate—urinary bladder cancer	4.7e-05	0.000478	CcSEcCtD
Losartan—Dyspepsia—Epirubicin—urinary bladder cancer	4.69e-05	0.000478	CcSEcCtD
Losartan—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.66e-05	0.000475	CcSEcCtD
Losartan—Decreased appetite—Epirubicin—urinary bladder cancer	4.64e-05	0.000472	CcSEcCtD
Losartan—Hypotension—Doxorubicin—urinary bladder cancer	4.61e-05	0.00047	CcSEcCtD
Losartan—Fatigue—Epirubicin—urinary bladder cancer	4.6e-05	0.000468	CcSEcCtD
Losartan—Constipation—Epirubicin—urinary bladder cancer	4.56e-05	0.000465	CcSEcCtD
Losartan—Pain—Epirubicin—urinary bladder cancer	4.56e-05	0.000465	CcSEcCtD
Losartan—Urticaria—Methotrexate—urinary bladder cancer	4.53e-05	0.000461	CcSEcCtD
Losartan—Abdominal pain—Methotrexate—urinary bladder cancer	4.51e-05	0.000459	CcSEcCtD
Losartan—Body temperature increased—Methotrexate—urinary bladder cancer	4.51e-05	0.000459	CcSEcCtD
Losartan—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.5e-05	0.000458	CcSEcCtD
Losartan—Insomnia—Doxorubicin—urinary bladder cancer	4.46e-05	0.000455	CcSEcCtD
Losartan—Paraesthesia—Doxorubicin—urinary bladder cancer	4.43e-05	0.000451	CcSEcCtD
Losartan—Dyspnoea—Doxorubicin—urinary bladder cancer	4.4e-05	0.000448	CcSEcCtD
Losartan—Feeling abnormal—Epirubicin—urinary bladder cancer	4.39e-05	0.000448	CcSEcCtD
Losartan—Somnolence—Doxorubicin—urinary bladder cancer	4.39e-05	0.000447	CcSEcCtD
Losartan—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.36e-05	0.000444	CcSEcCtD
Losartan—Dyspepsia—Doxorubicin—urinary bladder cancer	4.34e-05	0.000443	CcSEcCtD
Losartan—Decreased appetite—Doxorubicin—urinary bladder cancer	4.29e-05	0.000437	CcSEcCtD
Losartan—Fatigue—Doxorubicin—urinary bladder cancer	4.25e-05	0.000433	CcSEcCtD
Losartan—Urticaria—Epirubicin—urinary bladder cancer	4.24e-05	0.000432	CcSEcCtD
Losartan—Pain—Doxorubicin—urinary bladder cancer	4.22e-05	0.00043	CcSEcCtD
Losartan—Constipation—Doxorubicin—urinary bladder cancer	4.22e-05	0.00043	CcSEcCtD
Losartan—Abdominal pain—Epirubicin—urinary bladder cancer	4.22e-05	0.00043	CcSEcCtD
Losartan—Body temperature increased—Epirubicin—urinary bladder cancer	4.22e-05	0.00043	CcSEcCtD
Losartan—Hypersensitivity—Methotrexate—urinary bladder cancer	4.2e-05	0.000428	CcSEcCtD
Losartan—Asthenia—Methotrexate—urinary bladder cancer	4.09e-05	0.000417	CcSEcCtD
Losartan—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.07e-05	0.000414	CcSEcCtD
Losartan—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.04e-05	0.000411	CcSEcCtD
Losartan—Pruritus—Methotrexate—urinary bladder cancer	4.03e-05	0.000411	CcSEcCtD
Losartan—Hypersensitivity—Epirubicin—urinary bladder cancer	3.93e-05	0.0004	CcSEcCtD
Losartan—Urticaria—Doxorubicin—urinary bladder cancer	3.92e-05	0.000399	CcSEcCtD
Losartan—Body temperature increased—Doxorubicin—urinary bladder cancer	3.9e-05	0.000397	CcSEcCtD
Losartan—Abdominal pain—Doxorubicin—urinary bladder cancer	3.9e-05	0.000397	CcSEcCtD
Losartan—Diarrhoea—Methotrexate—urinary bladder cancer	3.9e-05	0.000397	CcSEcCtD
Losartan—Asthenia—Epirubicin—urinary bladder cancer	3.83e-05	0.00039	CcSEcCtD
Losartan—Pruritus—Epirubicin—urinary bladder cancer	3.77e-05	0.000384	CcSEcCtD
Losartan—Dizziness—Methotrexate—urinary bladder cancer	3.77e-05	0.000384	CcSEcCtD
Losartan—Diarrhoea—Epirubicin—urinary bladder cancer	3.65e-05	0.000372	CcSEcCtD
Losartan—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.64e-05	0.00037	CcSEcCtD
Losartan—Vomiting—Methotrexate—urinary bladder cancer	3.62e-05	0.000369	CcSEcCtD
Losartan—Rash—Methotrexate—urinary bladder cancer	3.59e-05	0.000366	CcSEcCtD
Losartan—Dermatitis—Methotrexate—urinary bladder cancer	3.59e-05	0.000366	CcSEcCtD
Losartan—Headache—Methotrexate—urinary bladder cancer	3.57e-05	0.000364	CcSEcCtD
Losartan—Asthenia—Doxorubicin—urinary bladder cancer	3.54e-05	0.000361	CcSEcCtD
Losartan—Dizziness—Epirubicin—urinary bladder cancer	3.53e-05	0.000359	CcSEcCtD
Losartan—Pruritus—Doxorubicin—urinary bladder cancer	3.49e-05	0.000356	CcSEcCtD
Losartan—Vomiting—Epirubicin—urinary bladder cancer	3.39e-05	0.000345	CcSEcCtD
Losartan—Nausea—Methotrexate—urinary bladder cancer	3.39e-05	0.000345	CcSEcCtD
Losartan—Diarrhoea—Doxorubicin—urinary bladder cancer	3.38e-05	0.000344	CcSEcCtD
Losartan—Rash—Epirubicin—urinary bladder cancer	3.36e-05	0.000343	CcSEcCtD
Losartan—Dermatitis—Epirubicin—urinary bladder cancer	3.36e-05	0.000342	CcSEcCtD
Losartan—Headache—Epirubicin—urinary bladder cancer	3.34e-05	0.00034	CcSEcCtD
Losartan—Dizziness—Doxorubicin—urinary bladder cancer	3.26e-05	0.000332	CcSEcCtD
Losartan—Nausea—Epirubicin—urinary bladder cancer	3.17e-05	0.000323	CcSEcCtD
Losartan—Vomiting—Doxorubicin—urinary bladder cancer	3.14e-05	0.00032	CcSEcCtD
Losartan—Rash—Doxorubicin—urinary bladder cancer	3.11e-05	0.000317	CcSEcCtD
Losartan—Dermatitis—Doxorubicin—urinary bladder cancer	3.11e-05	0.000317	CcSEcCtD
Losartan—Headache—Doxorubicin—urinary bladder cancer	3.09e-05	0.000315	CcSEcCtD
Losartan—Nausea—Doxorubicin—urinary bladder cancer	2.93e-05	0.000299	CcSEcCtD
Losartan—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.47e-06	7.54e-05	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	7.45e-06	7.51e-05	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—GSTM1—urinary bladder cancer	7.39e-06	7.46e-05	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—NCOR1—urinary bladder cancer	7.39e-06	7.46e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	7.37e-06	7.44e-05	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—CREBBP—urinary bladder cancer	7.36e-06	7.43e-05	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	7.28e-06	7.35e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	7.27e-06	7.34e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—ENO2—urinary bladder cancer	7.27e-06	7.34e-05	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—PPARG—urinary bladder cancer	7.22e-06	7.29e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.13e-06	7.19e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.11e-06	7.17e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—TYMP—urinary bladder cancer	7.09e-06	7.15e-05	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—GPX1—urinary bladder cancer	7.08e-06	7.14e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	7.06e-06	7.12e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	7.05e-06	7.12e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—NAT2—urinary bladder cancer	7.03e-06	7.1e-05	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—ERCC2—urinary bladder cancer	6.95e-06	7.01e-05	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—CREBBP—urinary bladder cancer	6.94e-06	7e-05	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	6.94e-06	7e-05	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	6.88e-06	6.94e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—NAT2—urinary bladder cancer	6.86e-06	6.93e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	6.85e-06	6.91e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.81e-06	6.87e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—RRM2—urinary bladder cancer	6.8e-06	6.86e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	6.77e-06	6.83e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	6.77e-06	6.83e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—RRM2—urinary bladder cancer	6.76e-06	6.82e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CREBBP—urinary bladder cancer	6.65e-06	6.71e-05	CbGpPWpGaD
Losartan—ALB—Hemostasis—CREBBP—urinary bladder cancer	6.57e-06	6.63e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—IGF1—urinary bladder cancer	6.56e-06	6.63e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—EGFR—urinary bladder cancer	6.53e-06	6.59e-05	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—MTHFR—urinary bladder cancer	6.53e-06	6.59e-05	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—PPARG—urinary bladder cancer	6.52e-06	6.58e-05	CbGpPWpGaD
Losartan—ALB—Hemostasis—IGF1—urinary bladder cancer	6.49e-06	6.55e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	6.48e-06	6.54e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—NAT2—urinary bladder cancer	6.41e-06	6.47e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	6.37e-06	6.42e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.35e-06	6.41e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	6.3e-06	6.35e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—ENO2—urinary bladder cancer	6.3e-06	6.35e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—ENO2—urinary bladder cancer	6.26e-06	6.32e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—HPGDS—urinary bladder cancer	6.26e-06	6.32e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.26e-06	6.32e-05	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—CREBBP—urinary bladder cancer	6.26e-06	6.32e-05	CbGpPWpGaD
Losartan—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.22e-06	6.28e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—KRAS—urinary bladder cancer	6.17e-06	6.23e-05	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	6.12e-06	6.17e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	6.11e-06	6.16e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.08e-06	6.13e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—GSTT1—urinary bladder cancer	6.07e-06	6.13e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—RRM2—urinary bladder cancer	6.07e-06	6.12e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—TYMP—urinary bladder cancer	6.06e-06	6.11e-05	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—PTGS2—urinary bladder cancer	6.03e-06	6.08e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—RHOA—urinary bladder cancer	6.01e-06	6.07e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.01e-06	6.07e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	6e-06	6.06e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	5.98e-06	6.04e-05	CbGpPWpGaD
Losartan—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.98e-06	6.03e-05	CbGpPWpGaD
Losartan—ALB—Hemostasis—RHOA—urinary bladder cancer	5.94e-06	6e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—RRM2—urinary bladder cancer	5.92e-06	5.98e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—NQO1—urinary bladder cancer	5.86e-06	5.91e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	5.85e-06	5.9e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.82e-06	5.87e-05	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.69e-06	5.74e-05	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—PTGS2—urinary bladder cancer	5.68e-06	5.73e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—ENO2—urinary bladder cancer	5.62e-06	5.67e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	5.62e-06	5.67e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.59e-06	5.64e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—ERBB2—urinary bladder cancer	5.57e-06	5.62e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—RRM2—urinary bladder cancer	5.53e-06	5.58e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—ENO2—urinary bladder cancer	5.49e-06	5.54e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—HPGDS—urinary bladder cancer	5.49e-06	5.54e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—NAT2—urinary bladder cancer	5.48e-06	5.53e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	5.45e-06	5.5e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.37e-06	5.42e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—GSTT1—urinary bladder cancer	5.32e-06	5.37e-05	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—PPARG—urinary bladder cancer	5.29e-06	5.34e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CXCL8—urinary bladder cancer	5.28e-06	5.33e-05	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—PTEN—urinary bladder cancer	5.26e-06	5.31e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—HRAS—urinary bladder cancer	5.25e-06	5.29e-05	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—PTGS2—urinary bladder cancer	5.13e-06	5.17e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	5.12e-06	5.17e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—ENO2—urinary bladder cancer	5.12e-06	5.17e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.09e-06	5.14e-05	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	5.09e-06	5.13e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—NQO1—urinary bladder cancer	5.08e-06	5.12e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—NQO1—urinary bladder cancer	5.05e-06	5.09e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—IL2—urinary bladder cancer	5.05e-06	5.09e-05	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—EP300—urinary bladder cancer	5.01e-06	5.06e-05	CbGpPWpGaD
Losartan—ALB—Hemostasis—IL2—urinary bladder cancer	4.99e-06	5.03e-05	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.98e-06	5.03e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	4.97e-06	5.02e-05	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—PTEN—urinary bladder cancer	4.95e-06	5e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.92e-06	4.97e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CCND1—urinary bladder cancer	4.92e-06	4.96e-05	CbGpPWpGaD
Losartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.9e-06	4.94e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.89e-06	4.94e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	4.89e-06	4.93e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	4.85e-06	4.9e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—MMP9—urinary bladder cancer	4.78e-06	4.82e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.76e-06	4.8e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—PTEN—urinary bladder cancer	4.75e-06	4.79e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—RRM2—urinary bladder cancer	4.73e-06	4.77e-05	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—EP300—urinary bladder cancer	4.72e-06	4.77e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.67e-06	4.72e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	4.66e-06	4.7e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—TYMS—urinary bladder cancer	4.54e-06	4.59e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—NQO1—urinary bladder cancer	4.53e-06	4.57e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—EP300—urinary bladder cancer	4.53e-06	4.57e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	4.49e-06	4.53e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	4.49e-06	4.53e-05	CbGpPWpGaD
Losartan—ALB—Hemostasis—EP300—urinary bladder cancer	4.47e-06	4.51e-05	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—PTEN—urinary bladder cancer	4.47e-06	4.51e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—NQO1—urinary bladder cancer	4.42e-06	4.46e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—SRC—urinary bladder cancer	4.4e-06	4.44e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.4e-06	4.44e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—ENO2—urinary bladder cancer	4.38e-06	4.42e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	4.38e-06	4.42e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.35e-06	4.39e-05	CbGpPWpGaD
Losartan—ALB—Hemostasis—SRC—urinary bladder cancer	4.35e-06	4.39e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—GPX1—urinary bladder cancer	4.3e-06	4.34e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.29e-06	4.33e-05	CbGpPWpGaD
Losartan—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.27e-06	4.31e-05	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—EP300—urinary bladder cancer	4.26e-06	4.3e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	4.25e-06	4.29e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	4.23e-06	4.27e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.23e-06	4.27e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	4.22e-06	4.26e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—GSTP1—urinary bladder cancer	4.21e-06	4.25e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.18e-06	4.22e-05	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	4.17e-06	4.2e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—NQO1—urinary bladder cancer	4.13e-06	4.17e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.1e-06	4.13e-05	CbGpPWpGaD
Losartan—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.07e-06	4.11e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.01e-06	4.04e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	3.97e-06	4.01e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—MYC—urinary bladder cancer	3.95e-06	3.98e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—TYMS—urinary bladder cancer	3.94e-06	3.97e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—TYMS—urinary bladder cancer	3.91e-06	3.95e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	3.89e-06	3.93e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	3.89e-06	3.93e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—GSTM1—urinary bladder cancer	3.87e-06	3.9e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—NCOR1—urinary bladder cancer	3.87e-06	3.9e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—EGFR—urinary bladder cancer	3.86e-06	3.89e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.83e-06	3.87e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	3.82e-06	3.85e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	3.78e-06	3.81e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—GPX1—urinary bladder cancer	3.73e-06	3.76e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—GPX1—urinary bladder cancer	3.7e-06	3.74e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—GSTP1—urinary bladder cancer	3.69e-06	3.72e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	3.66e-06	3.69e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.66e-06	3.69e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.65e-06	3.68e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—KRAS—urinary bladder cancer	3.65e-06	3.68e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—ERCC2—urinary bladder cancer	3.64e-06	3.67e-05	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—PTEN—urinary bladder cancer	3.63e-06	3.67e-05	CbGpPWpGaD
Losartan—ALB—Hemostasis—KRAS—urinary bladder cancer	3.6e-06	3.63e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.53e-06	3.56e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—TYMS—urinary bladder cancer	3.51e-06	3.55e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.5e-06	3.53e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	3.47e-06	3.5e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	3.47e-06	3.5e-05	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—EP300—urinary bladder cancer	3.46e-06	3.5e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.45e-06	3.48e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	3.44e-06	3.47e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—TYMS—urinary bladder cancer	3.43e-06	3.46e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.42e-06	3.46e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—MTHFR—urinary bladder cancer	3.42e-06	3.45e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—GSTM1—urinary bladder cancer	3.39e-06	3.42e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—NCOR1—urinary bladder cancer	3.39e-06	3.42e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.38e-06	3.41e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.38e-06	3.41e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.33e-06	3.36e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	3.33e-06	3.36e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—GPX1—urinary bladder cancer	3.33e-06	3.36e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.28e-06	3.31e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	3.26e-06	3.29e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—GPX1—urinary bladder cancer	3.25e-06	3.28e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—TP53—urinary bladder cancer	3.24e-06	3.27e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—PPARG—urinary bladder cancer	3.22e-06	3.25e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—TYMS—urinary bladder cancer	3.2e-06	3.23e-05	CbGpPWpGaD
Losartan—ALB—Hemostasis—TP53—urinary bladder cancer	3.2e-06	3.23e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—ERCC2—urinary bladder cancer	3.19e-06	3.22e-05	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—EP300—urinary bladder cancer	3.17e-06	3.2e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	3.17e-06	3.2e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	3.17e-06	3.2e-05	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—HRAS—urinary bladder cancer	3.1e-06	3.13e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	3.09e-06	3.12e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	3.07e-06	3.1e-05	CbGpPWpGaD
Losartan—ALB—Hemostasis—HRAS—urinary bladder cancer	3.06e-06	3.09e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—GPX1—urinary bladder cancer	3.03e-06	3.06e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—MTHFR—urinary bladder cancer	3e-06	3.02e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.99e-06	3.01e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.98e-06	3e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.94e-06	2.97e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.85e-06	2.87e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.8e-06	2.82e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—PPARG—urinary bladder cancer	2.79e-06	2.81e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—PPARG—urinary bladder cancer	2.77e-06	2.8e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.74e-06	2.76e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.72e-06	2.75e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.71e-06	2.73e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.71e-06	2.73e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	2.68e-06	2.7e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—CREBBP—urinary bladder cancer	2.66e-06	2.69e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.59e-06	2.61e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.54e-06	2.57e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	2.53e-06	2.56e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—PPARG—urinary bladder cancer	2.49e-06	2.51e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—PPARG—urinary bladder cancer	2.43e-06	2.45e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.39e-06	2.41e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	2.39e-06	2.41e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—CREBBP—urinary bladder cancer	2.33e-06	2.35e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.27e-06	2.29e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.27e-06	2.29e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—PTEN—urinary bladder cancer	2.21e-06	2.23e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	2.19e-06	2.21e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—PTGS2—urinary bladder cancer	2.18e-06	2.2e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.18e-06	2.2e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.11e-06	2.13e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—EP300—urinary bladder cancer	2.11e-06	2.13e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.09e-06	2.11e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.09e-06	2.11e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2e-06	2.02e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.96e-06	1.98e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.96e-06	1.98e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.94e-06	1.96e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.91e-06	1.93e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.91e-06	1.93e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—PTEN—urinary bladder cancer	1.9e-06	1.92e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.86e-06	1.88e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.85e-06	1.86e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.82e-06	1.84e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—EP300—urinary bladder cancer	1.81e-06	1.83e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.78e-06	1.8e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.71e-06	1.72e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.67e-06	1.68e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.63e-06	1.64e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—EP300—urinary bladder cancer	1.59e-06	1.6e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.56e-06	1.57e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.53e-06	1.54e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.5e-06	1.51e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.48e-06	1.5e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.44e-06	1.45e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.33e-06	1.34e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.27e-06	1.28e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.18e-06	1.19e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.03e-06	1.04e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—EP300—urinary bladder cancer	9.79e-07	9.88e-06	CbGpPWpGaD
